Product Data Sheet

AUY922 (NVP-AUY922)

Cat. No.: A4057
CAS No.: 747412-49-3
Formula: C26H31N3O5
M.Wt: 465.5
Synonyms: VER-52296, AUY-922, AUY 922
Target: Proteases
Pathway: HSP
Storage: Store at -20°C



Solvent & Solubility

In Vitro

⩾23.27 mg/mL in DMSO; insoluble in H2O; ⩾100.6 mg/mL in EtOH with ultrasonic

Preparing Stock Solutions

Concentration \ Mass / Solvent	1mg	5mg	10mg
1 mM	2.1482 mL	10.7411 mL	21.4823 mL
5 mM	0.4296 mL	2.1482 mL	4.2965 mL
10 mM	0.2148 mL	1.0741 mL	2.1482 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	Potent Hsp90 inhibitor
IC_{50} & Target	13 nM (HSP90α), 21 nM (HSP90β)

In Vitro

Cell Viability Assay

Cell Line:	NCI-N87, SNU-216 and SNU-484 cells
Preparation method:	The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.
Reacting conditions:	200 nM, 24 h

	Applications:	AUY922 reduced expression of client proteins. It decreased expression of receptor tyrosine kinases, such as VEGFR1, 2, 3 and PDGFR-α. It also decreased Akt and phospho-Akt in a dose-dependent manner. Besides that, AUY922 treatment resulted in decreased expression of HER-2 in NCI-N87 cells.
In Vivo	**Animal experiment**	
	Animal models:	Athymic Nude-nu mice injected with BT-474 breast cancer xenograft
	Dosage form:	Intravenous acute administration, 30 mg/kg
	Applications:	A significant effect of AUY922 on HSP90-p23 complex dissociation was observed at the 2- and 6-hour time points. From 16 and 24 hours after compound administration, HSP90-p23 complexes reassembled in the BT-474 xenografts. AUY922 also induced phospho-AKT level reduction.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Product Citations

1.Jason E. Gestwicki, Co-Chair, et al. "Strategies and functional consequences of inhibiting protein-protein interactions." University of Michigan. 2016.

See more customer validations on www.apexbt.com.

References

[1] Lee K H, Lee J H, Han S W, et al. Antitumor activity of NVP‐AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins. Cancer science, 2011, 102(7): 1388-1395.
[2] Jensen M R, Schoepfer J, Radimerski T, et al. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res, 2008, 10(2): R33.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology
www.apexbt.com
7505 Fannin street, Suite 410, Houston, TX 77054.
Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com